|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Enalapril#Patient Counseling Information]] |
| {{Enalapril}}
| |
| {{CMG}}; {{AE}} {{AM}}
| |
| | |
| ==Information for Patients==
| |
| | |
| ====Angioedema====
| |
| | |
| [[Angioedema]], including laryngeal edema, may occur at any time during treatment with angiotensin converting enzyme inhibitors, including enalapril. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips, tongue, difficulty in swallowing or breathing) and to take no more drug until they have consulted with the prescribing physician.
| |
| | |
| ====Hypotension====
| |
| | |
| Patients should be cautioned to report [[lightheadedness]], especially during the first few days of therapy. If actual syncope occurs, the patients should be told to discontinue the drug until they have consulted with the prescribing physician.
| |
| | |
| All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult with the physician.
| |
| | |
| ====Hyperkalemia====
| |
| | |
| Patients should be told not to use salt substitutes containing potassium without consulting their physician.
| |
| | |
| ====Neutropenia====
| |
| | |
| Patients should be told to report promptly any indication of infection (e.g., [[sore throat]], [[fever]]) which may be a sign of [[neutropenia]].
| |
| | |
| ====Pregnancy====
| |
| | |
| Female patients of childbearing age should be told about the consequences of exposure to [[ACE inhibitors]]. These patients should be asked to report pregnancies to their physicians as soon as possible.
| |
| | |
| NOTE: As with many other drugs, certain advice to patients being treated with enalapril is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VASOTEC (ENALAPRIL MALEATE) TABLET VASOTEC (ENALAPRIL MALEATE) TABLET [BTA PHARMACEUTICALS INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d181743-a0fc-4d17-953d-b17a936f9ecc | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |